NASDAQ:DXCM - Dexcom Stock Price, Price Target & More

$73.50 +0.08 (+0.11 %)

(As of 04/19/2018 07:54 AM ET)

Previous Close$73.42

Today's Range$73.21 - $74.62

52-Week Range$42.62 - $81.91

Volume771,400 shs

Average Volume1.27 million shs

Market Capitalization$6.39 billion

P/E Ratio-126.72

Dividend YieldN/A

Beta-0.01

About Dexcom (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:DXCM

CUSIP25213110

Webwww.dexcom.com

Phone858-200-0200

Debt

Debt-to-Equity Ratio0.78%

Current Ratio5.36%

Quick Ratio5.04%

Price-To-Earnings

Trailing P/E Ratio-126.72

Forward P/E Ratio-131.25

P/E GrowthN/A

Sales & Book Value

Annual Sales$718.50 million

Price / Sales8.90

Cash FlowN/A

Price / CashN/A

Book Value$4.83 per share

Price / Book15.22

Profitability

EPS (Most Recent Fiscal Year)($0.58)

Net Income$-50,200,000.00

Net Margins-6.99%

Return on Equity-13.99%

Return on Assets-6.67%

Miscellaneous

Employees2,990

Outstanding Shares87,000,000

How to Become a New Pot Stock Millionaire

Dexcom (NASDAQ:DXCM) Frequently Asked Questions

What is Dexcom's stock symbol?

Dexcom trades on the NASDAQ under the ticker symbol "DXCM."

How were Dexcom's earnings last quarter?

Dexcom (NASDAQ:DXCM) issued its earnings results on Tuesday, February, 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.07. The medical device company had revenue of $221 million for the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. View Dexcom's Earnings History.

When is Dexcom's next earnings date?

Dexcom is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Dexcom.

What price target have analysts set for DXCM?

21 brokerages have issued 1-year price targets for Dexcom's stock. Their forecasts range from $40.00 to $95.00. On average, they anticipate Dexcom's stock price to reach $67.3824 in the next twelve months. View Analyst Ratings for Dexcom.

Are investors shorting Dexcom?

Dexcom saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 14,147,733 shares, an increase of 17.6% from the March 15th total of 12,029,711 shares. Based on an average daily trading volume, of 1,435,600 shares, the short-interest ratio is currently 9.9 days. Approximately 16.7% of the shares of the company are short sold.

Who are some of Dexcom's key competitors?

Some companies that are related to Dexcom include Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX) and OraSure Technologies (OSUR).

Who are Dexcom's key executives?

Dexcom's management team includes the folowing people:

Mr. Kevin R. Sayer, Chief Exec. Officer, Pres and Director (Age 60)
Mr. Donald M. Abbey, Exec. VP of Quality & Information Technology (Age 51)
Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 46)
Mr. Richard B. Doubleday, Chief Commercial Officer and Exec. VP (Age 55)
Mr. Terrance H. Gregg, Exec. Chairman (Age 69)

Has Dexcom been receiving favorable news coverage?

News stories about DXCM stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dexcom earned a daily sentiment score of 0.03 on Accern's scale. They also assigned press coverage about the medical device company an impact score of 46.97 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Dexcom's major shareholders?

Dexcom's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARTISAN PARTNERS LIMITED PARTNERSHIP (2.30%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom.

How do I buy shares of Dexcom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dexcom's stock price today?

One share of DXCM stock can currently be purchased for approximately $73.50.

How big of a company is Dexcom?

Dexcom has a market capitalization of $6.39 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe.

How can I contact Dexcom?

Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

MarketBeat Community Rating for Dexcom (DXCM)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		578 (Vote Outperform)
Underperform Votes:		297 (Vote Underperform)
Total Votes:		875

MarketBeat's community ratings are surveys of what our community members think about Dexcom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Dexcom (NASDAQ:DXCM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

22 Wall Street analysts have issued ratings and price targets for Dexcom in the last 12 months. Their average twelve-month price target is $67.3824, suggesting that the stock has a possible downside of 8.32%. The high price target for DXCM is $95.00 and the low price target for DXCM is $40.00. There are currently 2 sell ratings, 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.57	2.57	2.64
Ratings Breakdown:	2 Sell Rating(s) 7 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$67.3824	$65.9706	$68.50	$72.1944
Price Target Upside:	8.32% downside	4.78% upside	20.70% upside	53.02% upside

Dexcom (NASDAQ:DXCM) Consensus Price Target History

Price Target History for Dexcom (NASDAQ:DXCM)

Dexcom (NASDAQ:DXCM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2018	Stephens	Reiterated Rating	Buy	$78.00	Medium
4/4/2018	Goldman Sachs	Initiated Coverage	Sell -> Sell	$74.69 -> $57.00	High
4/3/2018	Guggenheim	Initiated Coverage	Neutral -> Neutral		High
3/29/2018	Canaccord Genuity	Boost Price Target	Buy -> Positive	$71.00 -> $80.00	Medium
3/29/2018	BMO Capital Markets	Upgrade	Outperform	$78.00	Medium
3/29/2018	Oppenheimer	Set Price Target	Buy	$67.00 -> $80.00	Medium
3/29/2018	Piper Jaffray	Set Price Target	Buy	$80.00	Medium
3/23/2018	Robert W. Baird	Upgrade	Neutral -> Outperform	$58.00	High
3/4/2018	Northcoast Research	Reiterated Rating	Buy		High
1/16/2018	Northland Securities	Reiterated Rating	Sell	$40.00	Low
1/8/2018	Barclays	Reiterated Rating	Hold	$60.00	High
12/22/2017	Jefferies Group	Boost Price Target	Top Pick -> Buy	$58.00 -> $70.00	Low
11/3/2017	Morgan Stanley	Lower Price Target	Neutral	$72.00 -> $52.00	N/A
10/4/2017	Wedbush	Reiterated Rating	Buy	$76.00	Low
9/29/2017	Leerink Swann	Reiterated Rating	Buy	$85.00 -> $57.00	High
9/29/2017	Raymond James	Downgrade	Outperform -> Mkt Perform		High
9/28/2017	Cowen	Lower Price Target	Outperform	$90.00 -> $64.00	High
9/28/2017	Citigroup	Downgrade	Outperform -> Market Perform		High
9/28/2017	JPMorgan Chase	Downgrade	Overweight -> Neutral	$93.00 -> $71.00	High
5/7/2017	B. Riley	Reiterated Rating	Buy	$95.00	High
5/3/2017	BTIG Research	Downgrade	Buy -> Neutral		High
4/27/2017	William Blair	Reiterated Rating	Outperform		Low
4/4/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$87.00	Medium
12/19/2016	UBS	Upgrade	Market Perform -> Outperform		N/A
9/16/2016	Desjardins	Upgrade	Hold -> Buy		N/A
8/3/2016	Benchmark	Lower Price Target	Buy	$106.00 -> $86.00	N/A
7/15/2016	Deutsche Bank	Boost Price Target	Buy	$90.00 -> $98.00	N/A

(Data available from 4/19/2016 forward)

Dexcom (NASDAQ:DXCM) Earnings History and Estimates Chart

Earnings by Quarter for Dexcom (NASDAQ:DXCM)

Dexcom (NASDAQ:DXCM) Earnings Estimates

2018 EPS Consensus Estimate: ($0.41)
2019 EPS Consensus Estimate: ($0.28)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	6	($0.43)	($0.13)	($0.30)
Q2 2018	6	($0.26)	$0.05	($0.14)
Q3 2018	6	($0.16)	$0.15	($0.04)
Q4 2018	6	($0.04)	$0.28	$0.06
Q1 2019	2	($0.38)	($0.03)	($0.21)
Q2 2019	2	($0.13)	($0.02)	($0.08)
Q3 2019	2	($0.05)	($0.01)	($0.03)
Q4 2019	2	$0.01	$0.05	$0.03

Dexcom (NASDAQ DXCM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.28)					N/A
2/27/2018	Q4 2017	$0.03	$0.10	$217.82 million	$221.00 million	View	Listen
11/1/2017	Q3 2017	($0.15)	($0.04)	$183.42 million	$184.60 million	View	N/A
8/1/2017	Q2 2017	($0.23)	($0.16)	$166.54 million	$170.60 million	View	Listen
5/2/2017	Q1 2017	($0.55)	($0.49)	$143.94 million	$142.30 million	View	Listen
2/28/2017	Q416	($0.10)	($0.09)	$167.51 million	$171.20 million	View	Listen
11/1/2016	Q316	($0.14)	($0.22)	$146.09 million	$148.60 million	View	N/A
8/2/2016	Q216	($0.12)	($0.24)	$132.48 million	$137.30 million	View	N/A
4/27/2016	Q116	($0.20)	($0.23)	$110.37 million	$116.20 million	View	Listen
2/23/2016	Q415	$0.01	$0.02	$122.93 million	$130.80 million	View	Listen
11/4/2015	Q315	($0.01)	($0.07)	$97.47 million	$105.20 million	View	N/A
8/5/2015	Q215	($0.03)	($0.05)	$84.74 million	$93.20 million	View	N/A
4/29/2015	Q115	($0.11)	($0.17)	$71.32 million	$72.80 million	View	N/A
2/25/2015	Q414	($0.03)	$0.02	$79.65 million	$84.30 million	View	N/A
11/6/2014	Q314	($0.05)	($0.08)	$60.20 million	$67.90 million	View	N/A
8/6/2014	Q214	($0.10)	($0.10)	$52.45 million	$58.80 million	View	Listen
5/1/2014	Q114	($0.08)	($0.17)	$44.15 million	$47.10 million	View	Listen
2/20/2014	Q413	($0.07)	($0.04)	$48.53 million	$51.30 million	View	Listen
11/6/2013	Q313	($0.13)	($0.09)	$35.90 million	$42.90 million	View	N/A
8/7/2013	Q2 2013	($0.16)	($0.14)	$31.14 million	$35.80 million	View	N/A
5/1/2013	Q1 2013	($0.17)	($0.16)	$28.26 million	$29.60 million	View	N/A
2/21/2013	Q4 2012	($0.15)	($0.12)	$31.09 million	$33.30 million	View	N/A
11/1/2012	Q312	($0.22)	($0.25)	$23.14 million	$23.10 million	View	N/A
8/6/2012		($0.20)	($0.21)			View	N/A
5/2/2012		($0.19)	($0.21)			View	N/A
2/23/2012		($0.17)	($0.18)			View	N/A
11/2/2011		($0.15)	($0.20)			View	N/A
8/3/2011		($0.11)	($0.11)			View	N/A
5/3/2011		($0.19)	($0.19)			View	N/A
3/3/2011		($0.19)	($0.16)			View	N/A
11/4/2010	Q3 2010	($0.17)	($0.23)			View	N/A
8/3/2010	Q2 2010	($0.20)	($0.20)			View	N/A
5/5/2010	Q1 2010	($0.24)	($0.27)			View	N/A
3/9/2010	Q4 2009	($0.27)	($0.25)			View	N/A
11/4/2009	Q3 2009	($0.32)	($0.29)			View	N/A
8/3/2009	Q2 2009	($0.29)	($0.33)			View	N/A
5/6/2009	Q1 2009	($0.32)	($0.30)			View	N/A
3/5/2009	Q4 2008	($0.44)	($0.45)			View	N/A
11/10/2008	Q3 2008	($0.46)	($0.50)			View	N/A
8/5/2008	Q2 2008	($0.46)	($0.48)			View	N/A
5/8/2008	Q1 2008	($0.39)	($0.44)			View	N/A
3/11/2008	Q4 2007	($0.41)	($0.43)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Dexcom (NASDAQ:DXCM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Dexcom (NASDAQ DXCM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.70%

Insider Trading History for Dexcom (NASDAQ:DXCM)

Institutional Ownership by Quarter for Dexcom (NASDAQ:DXCM)

Dexcom (NASDAQ DXCM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Terrance H Gregg	Insider	Sell	10,000	$73.04	$730,400.00	521,674
3/23/2018	Richard Doubleday	EVP	Sell	2,581	$68.44	$176,643.64	94,429
3/15/2018	Terrance H Gregg	Insider	Sell	10,000	$65.51	$655,100.00	521,674
2/23/2018	Richard Doubleday	EVP	Sell	1,638	$56.32	$92,252.16	65,049
2/15/2018	Terrance H Gregg	Chairman	Sell	10,000	$55.91	$559,100.00	484,559
1/23/2018	Richard Doubleday	EVP	Sell	1,635	$54.67	$89,385.45	65,049
1/16/2018	Terrance H Gregg	Insider	Sell	10,000	$56.86	$568,600.00	484,559
12/26/2017	Richard Doubleday	EVP	Sell	1,635	$56.39	$92,197.65	65,049
12/12/2017	Kevin R. Sayer	CEO	Sell	6,000	$58.85	$353,100.00
12/11/2017	Andrew K. Balo	EVP	Sell	3,245	$61.23	$198,691.35
11/29/2017	Andrew K. Balo	EVP	Sell	6,490	$60.00	$389,400.00
11/27/2017	Mark G Foletta	Director	Sell	2,500	$54.95	$137,375.00	4,952
11/24/2017	Richard Doubleday	EVP	Sell	1,635	$55.53	$90,791.55	65,049
11/20/2017	Barbara Kahn	Director	Sell	3,000	$54.58	$163,740.00	4,353
11/20/2017	Kevin R. Sayer	CEO	Sell	12,000	$55.00	$660,000.00
11/6/2017	Steven R Altman	Director	Buy	10,000	$49.61	$496,100.00	4,353
10/23/2017	Richard Doubleday	EVP	Sell	1,635	$44.82	$73,280.70	65,049
9/25/2017	Steven Robert Pacelli	EVP	Sell	1,450	$69.81	$101,224.50
9/20/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.34	$416,040.00
9/11/2017	Andrew K. Balo	EVP	Sell	3,244	$72.27	$234,443.88
8/23/2017	Richard Doubleday	EVP	Sell	1,635	$75.26	$123,050.10	72,395
8/11/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.77	$418,620.00
8/10/2017	Andrew K. Balo	EVP	Sell	3,244	$71.18	$230,907.92
7/24/2017	Steven Robert Pacelli	EVP	Sell	1,450	$69.47	$100,731.50
7/12/2017	Kevin R. Sayer	CEO	Sell	6,000	$71.86	$431,160.00
7/10/2017	Andrew K. Balo	EVP	Sell	3,200	$71.55	$228,960.00
6/23/2017	Steven Robert Pacelli	EVP	Sell	1,450	$78.19	$113,375.50
6/12/2017	Andrew K. Balo	EVP	Sell	3,200	$69.06	$220,992.00
6/12/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.07	$414,420.00
5/23/2017	Richard Doubleday	EVP	Sell	3,182	$68.29	$217,298.78	72,395
5/17/2017	Kevin R Sayer	CEO	Sell	8,649	$68.39	$591,505.11	347,329
5/10/2017	Andrew K. Balo	EVP	Sell	3,200	$71.93	$230,176.00
4/24/2017	Richard Doubleday	EVP	Sell	3,182	$75.78	$241,131.96	97,815
4/20/2017	Terrance H Gregg	Insider	Sell	15,000	$74.10	$1,111,500.00	454,559
4/17/2017	Kevin R Sayer	CEO	Sell	10,000	$75.63	$756,300.00	353,680
4/10/2017	Andrew K. Balo	EVP	Sell	3,200	$78.19	$250,208.00
3/23/2017	Richard Doubleday	EVP	Sell	3,182	$76.38	$243,041.16	97,815
3/22/2017	Jess Roper	CFO	Sell	2,000	$75.97	$151,940.00	46,497
3/17/2017	Kevin R Sayer	CEO	Sell	10,000	$77.82	$778,200.00	353,680
3/14/2017	Jacob Steven Leach	SVP	Sell	21,317	$77.63	$1,654,838.71
3/13/2017	Jorge A. Valdes	Insider	Sell	14,400	$77.74	$1,119,456.00
3/9/2017	John Lister	Insider	Sell	3,000	$77.67	$233,010.00
3/6/2017	Jay S Skyler	Director	Sell	31,890	$78.13	$2,491,565.70	5,011
2/23/2017	Richard Doubleday	EVP	Sell	3,182	$78.42	$249,532.44	83,582
1/23/2017	Richard Doubleday	EVP	Sell	3,182	$79.50	$252,969.00	83,582
1/18/2017	Jess Roper	CFO	Sell	3,012	$85.01	$256,050.12	55,976
1/17/2017	Kevin R Sayer	CEO	Sell	10,000	$85.94	$859,400.00	309,391
1/13/2017	John Lister	Insider	Sell	15,000	$79.36	$1,190,400.00	85,598
1/10/2017	Andrew K Balo	EVP	Sell	3,200	$62.86	$201,152.00	109,545
1/9/2017	Jorge A Valdes	Insider	Sell	10,900	$63.02	$686,918.00	79,334
12/23/2016	Richard Doubleday	EVP	Sell	3,182	$62.17	$197,824.94	83,582
12/9/2016	Jorge A Valdes	Insider	Sell	10,000	$64.81	$648,100.00	74,971
10/24/2016	Jess Roper	CFO	Sell	2,471	$80.75	$199,533.25
10/24/2016	Steven Robert Pacelli	EVP	Sell	10,300	$81.95	$844,085.00
10/19/2016	Andrew K. Balo	EVP	Sell	4,997	$82.31	$411,303.07
10/14/2016	Kevin R. Sayer	CEO	Sell	7,000	$81.87	$573,090.00
10/10/2016	John Lister	Insider	Sell	3,560	$84.41	$300,499.60
10/5/2016	Andrew K. Balo	EVP	Sell	5,000	$82.55	$412,750.00
9/23/2016	Richard Doubleday	EVP	Sell	3,182	$93.97	$299,012.54	83,582
9/22/2016	Jess Roper	CFO	Sell	2,470	$93.99	$232,155.30
9/21/2016	Andrew K. Balo	EVP	Sell	5,000	$92.87	$464,350.00
9/14/2016	Kevin R. Sayer	CEO	Sell	7,000	$91.79	$642,530.00
9/12/2016	Jay S Skyler	Director	Sell	10,000	$93.00	$930,000.00	5,011
9/12/2016	Jorge A Valdes	Insider	Sell	19,071	$93.07	$1,774,937.97	103,667
9/9/2016	Jay S Skyler	Director	Sell	25,000	$94.07	$2,351,750.00	5,011
9/9/2016	John Lister	Insider	Sell	3,560	$93.65	$333,394.00
9/8/2016	Terrance H Gregg	Insider	Sell	10,740	$95.29	$1,023,414.60	451,486
9/7/2016	Andrew K Balo	EVP	Sell	4,999	$94.45	$472,155.55	135,009
9/7/2016	Mark G. Foletta	Director	Sell	1,800	$94.63	$170,334.00
9/1/2016	Jonathan T. Md Lord	Director	Sell	10,000	$91.50	$915,000.00
8/30/2016	Terrance H Gregg	Insider	Sell	10,000	$92.14	$921,400.00	451,486
8/24/2016	Andrew K Balo	EVP	Sell	5,000	$91.72	$458,600.00	134,979
8/24/2016	Terrance H Gregg	Insider	Sell	10,000	$92.72	$927,200.00	451,486
8/23/2016	Steven Robert Pacelli	EVP	Sell	10,300	$90.74	$934,622.00
8/23/2016	Terrance H Gregg	Chairman	Sell	10,000	$91.11	$911,100.00	451,486
8/22/2016	Terrance H Gregg	Chairman	Sell	10,000	$90.51	$905,100.00	451,486
8/19/2016	Jay S Skyler	Director	Sell	25,000	$90.77	$2,269,250.00	5,011
8/19/2016	Terrance H Gregg	Insider	Sell	40,000	$90.70	$3,628,000.00	451,486
8/15/2016	Kevin R. Sayer	CEO	Sell	7,000	$90.78	$635,460.00
8/15/2016	Terrance H Gregg	Chairman	Sell	14,942	$91.01	$1,359,871.42	451,486
8/12/2016	Jonathan T. Md Lord	Director	Sell	10,000	$90.64	$906,400.00
8/11/2016	Terrance H Gregg	Insider	Sell	10,900	$91.03	$992,227.00	451,486
8/10/2016	Andrew K Balo	EVP	Sell	5,000	$90.26	$451,300.00	134,979
8/9/2016	Jorge A Valdes	Insider	Sell	32,000	$91.06	$2,913,920.00	123,667
8/9/2016	Kevin R Sayer	CEO	Sell	20,000	$90.98	$1,819,600.00	362,227
8/8/2016	Barbara Kahn	Director	Sell	6,000	$90.52	$543,120.00	12,291
8/5/2016	Terrance H. Gregg	Insider	Sell	35,000	$79.81	$2,793,350.00
8/1/2016	Jeffrey Moy	SVP	Sell	15,000	$92.33	$1,384,950.00	107,582
7/27/2016	Andrew K Balo	EVP	Sell	5,000	$88.14	$440,700.00	134,979
7/25/2016	Richard Doubleday	EVP	Sell	3,182	$87.31	$277,820.42	92,250
7/22/2016	Jeffrey Moy	SVP	Sell	10,000	$88.48	$884,800.00	76,333
7/19/2016	Jeffrey Moy	SVP	Sell	12,843	$83.78	$1,075,986.54
7/13/2016	Andrew K Balo	EVP	Sell	5,000	$80.12	$400,600.00	134,979
7/13/2016	Kevin R. Sayer	CEO	Sell	7,000	$79.92	$559,440.00
7/11/2016	Jorge A Valdes	Insider	Sell	32,000	$79.36	$2,539,520.00	123,667
6/29/2016	Andrew K Balo	EVP	Sell	5,000	$78.10	$390,500.00	134,979
6/29/2016	Jeffrey Moy	SVP	Sell	4,557	$80.00	$364,560.00	76,333
6/23/2016	Steven Robert Pacelli	EVP	Sell	10,300	$77.40	$797,220.00
6/20/2016	Andrew K Balo	EVP	Sell	55,000	$75.00	$4,125,000.00	184,979
6/20/2016	Jeffrey Moy	SVP	Sell	7,209	$77.00	$555,093.00	76,333
6/20/2016	Kevin R. Sayer	CEO	Sell	35,000	$75.00	$2,625,000.00
6/9/2016	Jeffrey Moy	SVP	Sell	6,910	$74.00	$511,340.00	76,333
6/9/2016	John Lister	Insider	Sell	3,560	$73.27	$260,841.20	65,894
6/8/2016	Jeffrey Moy	SVP	Sell	6,866	$71.00	$487,486.00	76,333
6/8/2016	Jorge A Valdes	Insider	Sell	18,038	$72.06	$1,299,818.28	101,667
6/8/2016	Steven Robert Pacelli	EVP	Sell	18,239	$70.88	$1,292,780.32	182,518
6/7/2016	Jess Roper	CFO	Sell	3,471	$69.00	$239,499.00	85,248
5/23/2016	Richard Doubleday	EVP	Sell	1,674	$63.59	$106,449.66	94,900
5/18/2016	Jorge A Valdes	Insider	Sell	20,000	$61.75	$1,235,000.00	111,667
5/16/2016	Terrance H Gregg	Chairman	Sell	20,000	$62.72	$1,254,400.00	472,991
5/12/2016	Barbara Kahn	Director	Sell	3,000	$60.72	$182,160.00	42,804
5/11/2016	Terrance H Gregg	Chairman	Sell	8,600	$64.32	$553,152.00	472,991
5/9/2016	John Lister	Insider	Sell	3,560	$62.50	$222,500.00	69,454
5/9/2016	Terrance H Gregg	Chairman	Sell	12,168	$62.42	$759,526.56	472,991
4/27/2016	Jorge A Valdes	Insider	Sell	10,000	$70.00	$700,000.00	91,667
4/27/2016	Steven Robert Pacelli	EVP	Sell	2,361	$70.39	$166,190.79	201,757
4/25/2016	Jess Roper	CFO	Sell	3,471	$69.00	$239,499.00	88,719
4/25/2016	Richard Doubleday	EVP	Sell	1,666	$69.15	$115,203.90	94,900
4/12/2016	John Lister	Insider	Sell	3,704	$65.78	$243,649.12	73,014
4/11/2016	Terrance H Gregg	Chairman	Sell	2,169	$68.00	$147,492.00	475,159
4/4/2016	Jorge A Valdes	Insider	Sell	20,000	$70.08	$1,401,600.00	111,667
4/4/2016	Steven Robert Pacelli	EVP	Sell	20,600	$70.62	$1,454,772.00	204,118
3/31/2016	Jess Roper	CFO	Sell	3,470	$69.00	$239,430.00	92,190
3/23/2016	Richard Doubleday	EVP	Sell	1,666	$61.76	$102,892.16	123,022
3/22/2016	Terrance H Gregg	Chairman	Sell	25,000	$59.51	$1,487,750.00	477,328
3/14/2016	John Lister	Insider	Sell	3,560	$63.75	$226,950.00	80,278
3/7/2016	Barbara Kahn	Director	Sell	5,000	$67.04	$335,200.00	45,804
2/23/2016	Richard Doubleday	EVP	Sell	1,666	$64.36	$107,223.76	100,483
2/18/2016	John Lister	VP	Sell	3,560	$62.50	$222,500.00
1/25/2016	Steven Robert Pacelli	EVP	Sell	10,300	$73.24	$754,372.00	205,914
1/22/2016	Jess Roper	CFO	Sell	3,518	$72.97	$256,708.46	75,989
1/20/2016	Kevin R Sayer	CEO	Sell	7,000	$75.00	$525,000.00	336,402
1/12/2016	Jorge A Valdes	Insider	Sell	5,610	$80.16	$449,697.60	92,437
1/11/2016	Jorge A Valdes	Insider	Sell	1,641	$78.43	$128,703.63	92,437
1/8/2016	John Lister	VP	Sell	3,560	$82.57	$293,949.20	97,710
12/23/2015	Richard Doubleday	EVP	Sell	1,666	$82.22	$136,978.52	100,483
12/22/2015	Jess Roper	CFO	Sell	3,417	$81.19	$277,426.23	79,507
12/17/2015	Andrew K. Balo	EVP	Sell	7,500	$82.52	$618,900.00	107,680
12/14/2015	John Lister	VP	Sell	3,560	$82.50	$293,700.00	101,270
12/9/2015	Jorge A. Valdes	insider	Sell	10,000	$85.74	$857,400.00	92,437
12/8/2015	John Lister	VP	Sell	2,476	$87.16	$215,808.16	104,830
12/4/2015	Terrance H. Gregg	Chairman	Sell	10,000	$86.79	$867,900.00	459,018
12/3/2015	Andrew K. Balo	EVP	Sell	7,500	$86.37	$647,775.00	107,680
12/2/2015	Terrance H. Gregg	Chairman	Sell	10,000	$87.05	$870,500.00	459,018
11/30/2015	Terrance H. Gregg	Chairman	Sell	5,000	$86.50	$432,500.00	459,018
11/25/2015	Andrew K. Balo	EVP	Sell	7,500	$87.49	$656,175.00	107,680
11/25/2015	Terrance H. Gregg	Chairman	Sell	15,000	$87.53	$1,312,950.00	459,018
11/24/2015	Andrew K. Balo	EVP	Sell	10,000	$86.43	$864,300.00	107,680
11/24/2015	Terrance H. Gregg	Chairman	Sell	15,497	$86.54	$1,341,110.38	459,018
11/23/2015	Richard Doubleday	EVP	Sell	1,666	$85.85	$143,026.10	100,483
11/20/2015	Terrance H. Gregg	Chairman	Sell	22,003	$86.48	$1,902,819.44	459,018
11/18/2015	Jess Roper	CFO	Sell	7,000	$84.15	$589,050.00	82,924
11/16/2015	Terrance H. Gregg	Chairman	Sell	20,000	$83.89	$1,677,800.00	459,018
11/12/2015	Jess Roper	CFO	Sell	20,000	$84.07	$1,681,400.00	83,924
11/11/2015	Andrew K. Balo	EVP	Sell	7,500	$84.50	$633,750.00	113,157
10/23/2015	Richard Doubleday	EVP	Sell	1,666	$79.27	$132,063.82	100,483
10/20/2015	Andrew K Balo	EVP	Sell	4,538	$81.46	$369,665.48	113,157
10/19/2015	Jess Roper	CFO	Sell	7,000	$83.37	$583,590.00	98,424
10/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$77.92	$1,168,800.00	459,018
10/6/2015	Andrew K Balo	EVP	Sell	8,216	$82.29	$676,094.64	117,695
9/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$98.08	$1,373,120.00	216,214
9/21/2015	Andrew K Balo	EVP	Sell	7,859	$100.72	$791,558.48	125,911
9/18/2015	Jess Roper	CFO	Sell	7,000	$101.22	$708,540.00	99,424
9/15/2015	Terrance H. Gregg	Chairman	Sell	29,999	$96.22	$2,886,503.78	459,018
9/11/2015	Terrance H. Gregg	Chairman	Sell	47,500	$96.50	$4,583,750.00	459,018
9/10/2015	Terrance H. Gregg	Chairman	Sell	62,501	$95.91	$5,994,470.91	459,018
9/9/2015	Jonathan T Md Lord	Director	Sell	10,000	$90.96	$909,600.00	131,582
9/8/2015	Andrew K Balo	EVP	Sell	7,500	$89.53	$671,475.00	142,590
9/8/2015	John Lister	VP	Sell	2,642	$89.36	$236,089.12	121,347
9/8/2015	Terrance H. Gregg	Chairman	Sell	25,000	$90.85	$2,271,250.00	459,018
9/1/2015	Jeffrey Moy	SVP	Sell	8,881	$90.61	$804,707.41	90,000
9/1/2015	Jorge A. Valdes	insider	Sell	20,000	$91.22	$1,824,400.00	116,207
8/28/2015	Steven Robert Pacelli	EVP	Sell	19,854	$94.67	$1,879,578.18	228,792
8/24/2015	Steven Robert Pacelli	EVP	Sell	14,000	$84.18	$1,178,520.00	248,646
8/20/2015	Andrew K Balo	EVP	Sell	7,500	$92.47	$693,525.00	150,090
8/18/2015	Steven R Altman	Director	Sell	5,000	$96.69	$483,450.00
8/17/2015	Jay S Skyler	Director	Sell	20,000	$96.65	$1,933,000.00
8/17/2015	Terrance H Gregg	Chairman	Sell	15,000	$96.71	$1,450,650.00
8/14/2015	Kevin R Sayer	CEO	Sell	35,000	$97.41	$3,409,350.00
7/23/2015	Richard Doubleday	EVP	Sell	9,641	$85.37	$823,052.17
7/22/2015	Andrew K Balo	EVP	Sell	10,214	$84.78	$865,942.92
7/21/2015	Jeffrey Moy	SVP	Sell	3,786	$83.48	$316,055.28
7/20/2015	Jess Roper	CFO	Sell	7,000	$83.74	$586,180.00
7/17/2015	Terrance H Gregg	Chairman	Sell	50,750	$83.07	$4,215,802.50
7/15/2015	Jay S Skyler	Director	Sell	20,000	$81.69	$1,633,800.00
7/8/2015	Andrew K Balo	EVP	Sell	4,494	$80.22	$360,508.68
7/8/2015	John Lister	VP	Sell	1,776	$79.94	$141,973.44
7/8/2015	Jorge A Valdes	Insider	Sell	50,000	$79.83	$3,991,500.00
7/7/2015	Jeffrey Moy	SVP	Sell	5,000	$79.32	$396,600.00
6/23/2015	Jeffrey Moy	SVP	Sell	5,154	$77.54	$399,641.16
6/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$77.53	$1,085,420.00
6/18/2015	Jess Roper	CFO	Sell	7,000	$77.10	$539,700.00
6/15/2015	Jay S Skyler	Director	Sell	20,000	$70.67	$1,413,400.00
6/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$70.94	$1,064,100.00
6/12/2015	Terrance H. Gregg	Chairman	Sell	25,000	$72.30	$1,807,500.00	459,018
6/11/2015	Jeffrey Moy	SVP	Sell	9,869	$73.00	$720,437.00
6/9/2015	Andrew K Balo	EVP	Sell	7,500	$70.62	$529,650.00
6/9/2015	Jeffrey Moy	SVP	Sell	5,000	$70.63	$353,150.00
6/9/2015	Jorge A Valdes	Insider	Sell	19,680	$71.32	$1,403,577.60
6/8/2015	John Lister	VP	Sell	1,776	$72.03	$127,925.28
6/8/2015	Jorge A Valdes	Insider	Sell	8,243	$72.07	$594,073.01
6/3/2015	Terrance H Gregg	Chairman	Sell	40,000	$72.77	$2,910,800.00
6/2/2015	Terrance H Gregg	Chairman	Sell	5,000	$73.12	$365,600.00
6/1/2015	Terrance H Gregg	Chairman	Sell	10,000	$72.75	$727,500.00
5/27/2015	Jeffrey Moy	SVP	Sell	21,791	$69.60	$1,516,653.60
5/27/2015	Richard Doubleday	EVP	Sell	3,258	$70.73	$230,438.34
5/18/2015	Andrew K Balo	EVP	Sell	7,500	$68.46	$513,450.00
5/18/2015	Jeffrey Moy	SVP	Sell	15,586	$69.20	$1,078,551.20
5/18/2015	Jess Roper	CFO	Sell	7,000	$69.27	$484,890.00
5/15/2015	Terrance H Gregg	Chairman	Sell	82,500	$69.24	$5,712,300.00
5/12/2015	Jeffrey Moy	SVP	Sell	20,303	$67.84	$1,377,355.52
5/12/2015	Jorge A Valdes	Insider	Sell	30,878	$68.27	$2,108,041.06
5/11/2015	Jeffrey Moy	SVP	Sell	15,303	$68.25	$1,044,429.75
5/11/2015	Terrance H Gregg	Chairman	Sell	3,517	$68.65	$241,442.05
5/8/2015	Terrance H Gregg	Chairman	Sell	91,483	$67.85	$6,207,121.55
5/4/2015	Kevin R Sayer	CEO	Sell	25,000	$68.01	$1,700,250.00
4/28/2015	Jeffrey Moy	SVP	Sell	10,000	$68.41	$684,100.00
4/27/2015	Jeffrey Moy	SVP	Sell	5,000	$69.27	$346,350.00
4/23/2015	Steven Robert Pacelli	EVP	Sell	39,709	$69.63	$2,764,937.67
4/20/2015	Jess Roper	CFO	Sell	7,000	$68.05	$476,350.00
4/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$67.56	$1,013,400.00
4/14/2015	Jeffrey Moy	SVP	Sell	20,766	$66.63	$1,383,638.58
4/9/2015	Andrew K Balo	EVP	Sell	7,500	$64.55	$484,125.00
4/9/2015	Jorge A Valdes	Insider	Sell	19,684	$64.38	$1,267,255.92
4/8/2015	John Lister	VP	Sell	5,039	$63.84	$321,689.76
3/25/2015	Andrew K Balo	EVP	Sell	7,500	$61.05	$457,875.00
3/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$61.33	$858,620.00
3/18/2015	Jess Roper	CFO	Sell	7,000	$62.43	$437,010.00
3/17/2015	Terrance H Gregg	Chairman	Sell	15,000	$62.82	$942,300.00
3/13/2015	Jay S Skyler	Director	Sell	45,000	$60.01	$2,700,450.00
3/12/2015	Jorge A Valdes	Insider	Sell	11,138	$59.78	$665,829.64
3/12/2015	Richard Doubleday	EVP	Sell	20,000	$59.23	$1,184,600.00
3/9/2015	John Lister	VP	Sell	5,039	$58.77	$296,142.03
3/9/2015	Jorge A Valdes	Insider	Sell	8,244	$58.77	$484,499.88
2/23/2015	Richard Doubleday	EVP	Sell	4,000	$63.58	$254,320.00
2/9/2015	John Lister	VP	Sell	5,039	$61.66	$310,704.74
2/9/2015	Jorge A Valdes	Insider	Sell	8,244	$61.67	$508,407.48
2/2/2015	Jeffrey Moy	SVP	Sell	5,000	$60.69	$303,450.00
1/26/2015	Steven Robert Pacelli	EVP	Sell	24,532	$59.67	$1,463,824.44
1/23/2015	Richard Doubleday	EVP	Sell	4,000	$58.22	$232,880.00
1/20/2015	Jeffrey Moy	SVP	Sell	5,000	$57.58	$287,900.00
1/20/2015	Jess Roper	CFO	Sell	7,000	$57.34	$401,380.00
1/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$57.84	$867,600.00
1/13/2015	Steven Robert Pacelli	EVP	Sell	9,468	$62.22	$589,098.96
1/12/2015	Steven Robert Pacelli	EVP	Sell	20,000	$59.18	$1,183,600.00
1/9/2015	Jorge A Valdes	Insider	Sell	9,170	$57.55	$527,733.50
1/8/2015	John Lister	VP	Sell	5,039	$57.42	$289,339.38
1/5/2015	Jeffrey Moy	SVP	Sell	5,000	$55.27	$276,350.00
12/26/2014	Andrew K Balo	SVP	Sell	10,000	$55.27	$552,700.00
12/23/2014	Richard Doubleday	VP	Sell	4,000	$54.69	$218,760.00
12/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$54.62	$764,680.00
12/18/2014	Jess Roper	CFO	Sell	12,000	$56.43	$677,160.00
12/15/2014	Terrance H Gregg	CEO	Sell	35,000	$53.23	$1,863,050.00
12/8/2014	Jorge A Valdes	Insider	Sell	16,000	$56.03	$896,480.00
12/3/2014	Eric Topol	Director	Sell	20,000	$55.00	$1,100,000.00
11/28/2014	Terrance H Gregg	CEO	Sell	59,990	$51.51	$3,090,084.90
11/25/2014	Andrew K Balo	SVP	Sell	10,000	$51.11	$511,100.00
11/25/2014	Terrance H Gregg	CEO	Sell	55,010	$51.04	$2,807,710.40
11/24/2014	Richard Doubleday	VP	Sell	4,000	$50.36	$201,440.00
11/24/2014	Terrance H Gregg	CEO	Sell	35,000	$51.06	$1,787,100.00
11/21/2014	Terrance H Gregg	CEO	Sell	10,000	$50.50	$505,000.00
11/19/2014	Terrance H Gregg	CEO	Sell	10,000	$51.00	$510,000.00
11/17/2014	Terrance H Gregg	CEO	Sell	45,000	$52.52	$2,363,400.00
11/12/2014	Terrance H Gregg	CEO	Sell	80,000	$53.36	$4,268,800.00
11/10/2014	Jorge A Valdes	Insider	Sell	16,000	$51.23	$819,680.00
10/27/2014	Andrew K Balo	SVP	Sell	10,000	$42.98	$429,800.00
10/23/2014	Richard Doubleday	VP	Sell	4,000	$43.58	$174,320.00
10/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$43.60	$610,400.00
10/13/2014	Andrew K Balo	SVP	Sell	10,000	$40.42	$404,200.00
10/13/2014	John Lister	VP	Sell	3,400	$40.41	$137,394.00
10/8/2014	Jorge A Valdes	Insider	Sell	16,000	$40.29	$644,640.00
9/25/2014	Andrew K Balo	SVP	Sell	10,000	$40.71	$407,100.00
9/23/2014	Richard Doubleday	VP	Sell	4,000	$40.32	$161,280.00
9/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$40.32	$564,480.00
9/18/2014	Jess Roper	CFO	Sell	8,000	$41.91	$335,280.00
9/15/2014	Terrance H Gregg	CEO	Sell	35,000	$41.14	$1,439,900.00
9/12/2014	John Lister	VP	Sell	3,518	$43.70	$153,736.60
9/11/2014	Andrew K Balo	SVP	Sell	10,000	$42.97	$429,700.00
9/8/2014	Jorge A Valdes	Insider	Sell	16,000	$42.98	$687,680.00
8/28/2014	Barbara Kahn	Director	Sell	4,000	$44.52	$178,080.00
8/26/2014	Jeffrey Moy	SVP	Sell	16,663	$45.30	$754,833.90
8/26/2014	Jonathan T Md Lord	Director	Sell	20,000	$45.56	$911,200.00
8/26/2014	Steven Robert Pacelli	EVP	Sell	30,000	$44.56	$1,336,800.00
8/26/2014	Terrance H Gregg	CEO	Sell	5,000	$46.05	$230,250.00
8/25/2014	Andrew K Balo	SVP	Sell	10,000	$44.12	$441,200.00
8/25/2014	Richard Doubleday	VP	Sell	4,000	$44.35	$177,400.00
8/25/2014	Steven Robert Pacelli	EVP	Sell	14,000	$44.24	$619,360.00
8/22/2014	Andrew K Balo	SVP	Sell	20,000	$44.24	$884,800.00
8/22/2014	Terrance H Gregg	CEO	Sell	13,607	$44.46	$604,967.22
8/21/2014	Barbara Kahn	Director	Sell	2,200	$43.42	$95,524.00
8/21/2014	Jorge A Valdes	Insider	Sell	10,671	$43.58	$465,042.18
8/21/2014	Terrance H Gregg	CEO	Sell	23,893	$44.36	$1,059,893.48
8/19/2014	Richard Doubleday	VP	Sell	20,000	$45.01	$900,200.00
8/19/2014	Terrance H Gregg	CEO	Sell	75,000	$45.08	$3,381,000.00
8/18/2014	Terrance H Gregg	CEO	Sell	65,000	$44.16	$2,870,400.00
8/14/2014	Terrance H Gregg	CEO	Sell	25,000	$44.24	$1,106,000.00
8/13/2014	Terrance H Gregg	CEO	Sell	56,107	$43.57	$2,444,581.99
8/11/2014	Andrew K Balo	SVP	Sell	10,000	$44.24	$442,400.00
8/11/2014	Kevin R Sayer	COO	Sell	20,000	$43.82	$876,400.00
8/8/2014	Jorge A Valdes	Insider	Sell	16,000	$43.56	$696,960.00
7/25/2014	Andrew K Balo	SVP	Sell	10,000	$38.19	$381,900.00
7/23/2014	Richard Doubleday	VP	Sell	4,000	$38.16	$152,640.00
7/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$38.28	$535,920.00
7/18/2014	Jess Roper	CFO	Sell	8,000	$36.01	$288,080.00
7/15/2014	Terrance H Gregg	CEO	Sell	35,000	$36.66	$1,283,100.00
7/14/2014	John Lister	VP	Sell	3,500	$36.59	$128,065.00
7/11/2014	Andrew K Balo	SVP	Sell	10,000	$35.93	$359,300.00
7/8/2014	Jorge A Valdes	Insider	Sell	16,000	$36.66	$586,560.00
7/2/2014	Jay S Skyler	Director	Sell	30,000	$40.05	$1,201,500.00
6/25/2014	Andrew K Balo	SVP	Sell	10,000	$40.60	$406,000.00
6/23/2014	Richard Doubleday	VP	Sell	4,000	$40.98	$163,920.00
6/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$41.02	$574,280.00
6/20/2014	Jay S Skyler	Director	Sell	60,000	$40.00	$2,400,000.00
6/18/2014	Jess Roper	CFO	Sell	8,000	$39.17	$313,360.00
6/16/2014	Terrance H Gregg	CEO	Sell	35,000	$37.23	$1,303,050.00
6/12/2014	John Lister	VP	Sell	3,500	$36.13	$126,455.00
6/11/2014	Andrew K Balo	SVP	Sell	10,000	$36.63	$366,300.00
6/9/2014	Jorge A Valdes	Insider	Sell	16,000	$36.68	$586,880.00
6/5/2014	Richard Doubleday	VP	Sell	4,000	$35.59	$142,360.00
5/27/2014	Andrew K Balo	SVP	Sell	10,000	$33.86	$338,600.00
5/19/2014	Jess Roper	CFO	Sell	8,000	$32.20	$257,600.00	87,786
5/8/2014	Jorge Valdes	Insider	Sell	16,000	$29.83	$477,280.00	217,487
4/25/2014	Andrew Balo	SVP	Sell	10,000	$34.35	$343,500.00	159,099
4/23/2014	Richard Doubleday	VP	Sell	4,000	$35.92	$143,680.00	147,523
4/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$35.90	$502,600.00	241,399
4/21/2014	Jess Roper	CFO	Sell	8,000	$36.18	$289,440.00	87,786
4/15/2014	Terrance Gregg	CEO	Sell	35,000	$34.09	$1,193,150.00	395,626
4/14/2014	John Lister	VP	Sell	2,884	$35.86	$103,420.24	119,408
4/11/2014	Andrew Balo	SVP	Sell	10,000	$35.36	$353,600.00	159,099
4/8/2014	Jorge Valdes	Insider	Sell	16,000	$35.99	$575,840.00	217,487
3/26/2014	Jay Skyler	Director	Sell	30,000	$43.05	$1,291,500.00
3/25/2014	Andrew Balo	SVP	Sell	10,000	$43.00	$430,000.00	159,099
3/24/2014	Steven Robert Pacelli	EVP	Sell	14,000	$42.92	$600,880.00	241,399
3/18/2014	Jess Roper	CFO	Sell	8,000	$46.00	$368,000.00	87,786
3/17/2014	Terrance Gregg	CEO	Sell	45,000	$45.25	$2,036,250.00	395,626
3/12/2014	Terrance Gregg	CEO	Sell	30,000	$45.50	$1,365,000.00	395,626
3/10/2014	Jorge Valdes	Insider	Sell	16,000	$46.57	$745,120.00	203,003
3/5/2014	Jeffrey Moy	SVP	Sell	10,000	$47.30	$473,000.00	187,485
3/5/2014	Terrance Gregg	CEO	Sell	111,890	$47.46	$5,310,299.40	212,813
3/3/2014	Terrance Gregg	CEO	Sell	40,000	$44.87	$1,794,800.00	212,813
2/26/2014	Jess Roper	CFO	Sell	25,000	$45.20	$1,130,000.00	66,508
2/25/2014	Steven Robert Pacelli	EVP	Sell	33,368	$44.93	$1,499,224.24	195,865
1/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$36.49	$510,860.00	195,865
1/21/2014	Jess Roper	CFO	Sell	8,000	$37.38	$299,040.00	65,808
12/18/2013	Jess Roper	CFO	Sell	8,000	$34.48	$275,840.00	65,808
12/13/2013	Terrance Gregg	CEO	Sell	50,000	$34.41	$1,720,500.00	212,813
12/12/2013	Nicholas Augustinos	Director	Sell	11,321	$34.40	$389,442.40	11,130
12/10/2013	Nicholas Augustinos	Director	Sell	97,541	$33.64	$3,281,279.24	22,451
12/5/2013	Terrance Gregg	CEO	Sell	20,000	$34.77	$695,400.00	212,813
12/3/2013	Andrew Balo	SVP	Sell	14,268	$34.21	$488,108.28	124,297
11/15/2013	Terrance Gregg	CEO	Sell	35,000	$32.74	$1,145,900.00	212,813
9/3/2013	Terrance Gregg	CEO	Sell	9,000	$27.00	$243,000.00	212,813
8/1/2013	Terrance H Gregg	CEO	Sell	9,000	$22.15	$199,350.00
7/1/2013	Terrance H Gregg	CEO	Sell	9,000	$22.87	$205,830.00
6/13/2013	Andrew K Balo	SVP	Sell	10,000	$21.90	$219,000.00
6/11/2013	Jess Roper	CFO	Sell	10,361	$22.33	$231,361.13
6/11/2013	John Lister	VP	Sell	2,000	$22.43	$44,860.00
6/11/2013	Steven Robert Pacelli	EVP	Sell	5,000	$22.31	$111,550.00
6/4/2013	Terrance H Gregg	CEO	Sell	19,000	$21.32	$405,080.00
5/15/2013	Jeffrey Moy	SVP	Sell	5,000	$19.97	$99,850.00
5/13/2013	Andrew K Balo	SVP	Sell	45,000	$19.40	$873,000.00
5/9/2013	Richard Doubleday	SVP	Sell	1,272	$19.56	$24,880.32
3/13/2013	Andrew K Balo	SVP	Sell	15,416	$16.53	$254,826.48
3/11/2013	Jay S Skyler	Director	Buy	70,000	$15.50	$1,085,000.00
3/11/2013	John Lister	VP	Sell	4,500	$15.75	$70,875.00
3/11/2013	Richard Doubleday	SVP	Sell	5,100	$15.63	$79,713.00
2/1/2013	Terrance H Gregg	CEO	Sell	9,000	$15.08	$135,720.00
12/3/2012	Terrance H Gregg	CEO	Sell	5,000	$13.24	$66,200.00
9/4/2012	Terrance H Gregg	CEO	Sell	15,000	$13.46	$201,900.00

(Data available from 1/1/2013 forward)

Dexcom (NASDAQ DXCM) News Headlines

Source:

Date	Headline
	Insider Selling: Dexcom (DXCM) Insider Sells 10,000 Shares of Stock www.americanbankingnews.com - April 18 at 10:10 PM
	Dexcom (DXCM) Raised to Hold at Zacks Investment Research www.americanbankingnews.com - April 17 at 5:27 PM
	Dexcom (DXCM) Downgraded by BidaskClub www.americanbankingnews.com - April 16 at 6:31 PM
	BidaskClub Downgrades Dexcom (DXCM) to Strong Sell www.americanbankingnews.com - April 14 at 5:51 PM
	Dexcom (DXCM) Given a $92.00 Price Target at Oppenheimer www.americanbankingnews.com - April 14 at 11:49 AM
	Dexcom's (DXCM) Outperform Rating Reiterated at BMO Capital Markets www.americanbankingnews.com - April 14 at 9:59 AM
	TheStreet Upgrades Dexcom (DXCM) to C- www.americanbankingnews.com - April 13 at 10:53 AM
	This Morning's Technical Outlook on Medical Research Stocks -- Bruker, Charles River Labs, DexCom, and Exact ... www.prnewswire.com - April 12 at 10:07 AM
	Edited Transcript of DXCM presentation 6-Mar-17 9:00pm GMT finance.yahoo.com - April 12 at 10:07 AM
	Dexcom (DXCM) Sees Significant Growth in Short Interest www.americanbankingnews.com - April 12 at 2:18 AM
	BidaskClub Upgrades Dexcom (DXCM) to Sell www.americanbankingnews.com - April 11 at 10:10 PM
	Analysts Anticipate Dexcom (DXCM) Will Post Quarterly Sales of $172.68 Million www.americanbankingnews.com - April 11 at 6:05 AM
	Dexcom's (DXCM) Buy Rating Reaffirmed at Stephens www.americanbankingnews.com - April 9 at 1:19 PM
	DexCom (DXCM): Notes From Mass General Expert Call - Piper Jaffray www.streetinsider.com - April 9 at 9:30 AM
	UPDATE: DexCom (DXCM) PT Raised to $78 at Stephens; Reiterates Overweight www.streetinsider.com - April 9 at 9:30 AM
	-$0.32 Earnings Per Share Expected for Dexcom (DXCM) This Quarter www.americanbankingnews.com - April 9 at 1:22 AM
	DexCom Schedules First Quarter 2018 Earnings Release and Conference Call for May 2, 2018 at 4:30 pm Eastern Time. www.businesswire.com - April 4 at 4:53 PM
	DexCom Schedules First Quarter 2018 Earnings Release and Conference Call for May 2, 2018 at 4:30 p.m. Eastern Time. finance.yahoo.com - April 4 at 4:53 PM
	Here's Why Senseonics Holdings Inc. Is Rising Today finance.yahoo.com - April 4 at 4:53 PM
	Dexcom (DXCM) Now Covered by Analysts at Goldman Sachs www.americanbankingnews.com - April 4 at 8:04 AM
	Dexcom (DXCM) Receives New Coverage from Analysts at Guggenheim www.americanbankingnews.com - April 3 at 9:18 PM
	Jefferies Has 4 Health Care and Technology Stock Buys to Start Q2 247wallst.com - April 3 at 9:34 AM
	DexCom Is A Takeover Candidate - Cramer's Lightning Round (3/29/18) seekingalpha.com - April 2 at 9:45 AM
	Dexcom (DXCM) Given New $57.00 Price Target at Barclays www.americanbankingnews.com - April 1 at 10:20 PM
	Dexcom (DXCM) Raised to Hold at ValuEngine www.americanbankingnews.com - April 1 at 7:35 PM
	DexCom, Inc. (DXCM) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 31 at 5:42 AM
	DexCom (DXCM) Lifted to Strong-Buy at BidaskClub www.americanbankingnews.com - March 30 at 6:14 PM
	DexCom (DXCM) Given a $80.00 Price Target by Piper Jaffray Analysts www.americanbankingnews.com - March 29 at 11:25 AM
	DexCom (DXCM) PT Set at $80.00 by Oppenheimer www.americanbankingnews.com - March 29 at 11:11 AM
	DexCom (DXCM) Upgraded to "Outperform" by BMO Capital Markets www.americanbankingnews.com - March 29 at 8:36 AM
	DexCom (DXCM) Given "Positive" Rating at Canaccord Genuity www.americanbankingnews.com - March 29 at 8:36 AM
	DexCom (DXCM) PT Raised to $80 at Piper Jaffray, Recommends Buying Shares www.streetinsider.com - March 28 at 4:34 PM
	DexCom (DXCM) PT Raised to $85 at Cowen on FDA Approval of G6 CGM System; 'Upside to 2018/2019 Revenue ... www.streetinsider.com - March 28 at 4:34 PM
	DexCom's (DXCM) Sell Rating Reaffirmed at Northland Securities www.americanbankingnews.com - March 28 at 12:58 PM
	FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes finance.yahoo.com - March 28 at 9:31 AM
	Richard Doubleday Sells 2,581 Shares of DexCom, Inc. (DXCM) Stock www.americanbankingnews.com - March 27 at 10:33 PM
	FDA approves DexCom's glucose monitoring system finance.yahoo.com - March 27 at 4:30 PM
	FDA OKs DexCom G6 integrated CGM system seekingalpha.com - March 27 at 4:26 PM
	DexCom (DXCM) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 27 at 3:30 PM
	Today’s Research Reports on Trending Tickers: DexCom and Solid Biosciences finance.yahoo.com - March 26 at 9:41 AM
	Analysts Anticipate DexCom, Inc. (DXCM) Will Post Quarterly Sales of $172.80 Million www.americanbankingnews.com - March 25 at 9:58 AM
	DexCom (DXCM) Downgraded to Hold at BidaskClub www.americanbankingnews.com - March 25 at 12:16 AM
	Baird Upgrades DexCom (DXCM) to Outperform www.streetinsider.com - March 24 at 4:33 PM
	DexCom (DXCM) Given Buy Rating at Northcoast Research www.americanbankingnews.com - March 24 at 12:06 PM
	Piper Jaffray Companies Analysts Give DexCom (DXCM) a $78.00 Price Target www.americanbankingnews.com - March 23 at 6:50 PM
	DexCom (DXCM) Rating Increased to Outperform at Robert W. Baird www.americanbankingnews.com - March 23 at 6:49 PM
	Brokers Issue Forecasts for DexCom, Inc.'s Q1 2019 Earnings (DXCM) www.americanbankingnews.com - March 23 at 12:51 PM
	-$0.32 Earnings Per Share Expected for DexCom, Inc. (DXCM) This Quarter www.americanbankingnews.com - March 23 at 1:14 AM
	FY2021 EPS Estimates for DexCom, Inc. (DXCM) Increased by Analyst www.americanbankingnews.com - March 22 at 5:52 PM
	DexCom, Inc. (DXCM) Insider Terrance H. Gregg Sells 10,000 Shares www.americanbankingnews.com - March 19 at 10:10 PM

Dexcom (NASDAQ:DXCM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Dexcom (NASDAQ:DXCM) Income Statement, Balance Sheet and Cash Flow Statement

Dexcom (NASDAQ DXCM) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff